Radiolabeled Compounds for Neurodegenerative Disease Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for neurodegenerative diseases like Parkinson's lack specific tracers for early detection of alpha-synuclein aggregates, hindering early diagnosis and effective monitoring.
Innovation Solution
Development of radiolabeled compounds with affinity for alpha-synuclein, beta-amyloid, and tau fibers, utilizing fluorine-18 (18F) or other radioelements for PET/SPECT imaging to detect and quantify these protein aggregates in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radiolabeled tracers are used for PET/SPECT imaging, then early detection capability is improved, but specific tracers for alpha-synuclein aggregates are not available
Solution Approach 1:
The patent modifies the chemical structure of compounds by changing parameters such as substituting aromatic rings with different heteroatoms, adjusting linker lengths, and varying functional groups to optimize binding affinity and selectivity for alpha-synuclein aggregates while maintaining radiolabeling capability
Solution Approach 2:
The patent creates composite radiotracers by combining radioactive isotopes (18F, 11C, 123I, 124I) with organic ligand structures that have specific affinity for alpha-synuclein aggregates, forming hybrid molecules that possess both detectability and target-specific binding properties
2Reliability
If clinical imaging methods are used, then diagnosis can be performed, but early stage aggregates cannot be detected
Solution Approach 1:
The patent enables preliminary detection of alpha-synuclein aggregates before clinical symptoms appear by using radiolabeled tracers that can detect early-stage aggregates, allowing diagnosis and intervention to occur earlier in the disease progression timeline
3Ease of operation
If current diagnostic methods are used, then clinical criteria can be applied, but molecular imaging tracers for alpha-synuclein are unavailable
Solution Approach 1:
The patent introduces radiolabeled compounds as intermediary molecules that bridge the gap between clinical imaging technology and alpha-synuclein aggregates, enabling the imaging equipment to detect the aggregates indirectly through the tracer molecules that specifically bind to them
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early and accurate diagnosis of neurodegenerative diseases by specifically binding to protein aggregates, improving monitoring and treatment evaluation through enhanced imaging capabilities.
Implementation Method 1
radiation emitters β+ or γ and specific for the target to explore
Implementation Method 2
positron emission tomography (PET)
Implementation Method 3
single photon emission computed tomography (SPECT)
Data Source
AI summary
The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases.